Modulatory effect of acetyl-l-carnitine on amyloid precursor protein metabolism in hippocampal neurons

European Journal of Pharmacology

Volumn 597, Issue 1-3, 2008, Pages 51-56

  Epis, Roberta ^a   Marcello, Elena ^a   Gardoni, Fabrizio ^a   Longhi, Annalisa ^a   Calvani, Menotti ^b   Iannuccelli, Maurizio ^b   Cattabeni, Flaminio ^a   Canonico, Pier L ^c   Di Luca, Monica ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Sigma Tau SpA   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Acetylcarnitine; ADAM10; Alzheimer's disease; Amyloid precursor protein

Indexed keywords

ACETYLCARNITINE; ADAM 10 PROTEIN; ADAM PROTEIN; ALPHA SECRETASE; AMYLOID PRECURSOR PROTEIN; LEVACECARNINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; HIPPOCAMPUS; HUMAN; IN VITRO STUDY; NEUROBLASTOMA; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; RAT;

ACETYLCARNITINE; ADAM PROTEINS; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CELL LINE, TUMOR; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HIPPOCAMPUS; HUMANS; NEURONS; NEUROPROTECTIVE AGENTS; PROTEIN TRANSPORT; RATS; TIME FACTORS;

EID: 53449093489     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.09.001     Document Type: Article

References (40)

1. Abdul H.M., Calabrese V., Calvani M., and Butterfield D.A. Acetyl-l-carnitine-induced up-regulation of heat shock proteins protects cortical neurons against amyloid-beta peptide 1-42-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease. J. Neurosci. Res. 84 (2006) 398-408
2. Adlard P.A., Perreau V.M., Pop V., and Cotman C.W. Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J. Neurosci. 25 (2005) 4217-4221
3. Aureli T., Di Cocco M.E., Puccetti C., Ricciolini R., Scalibastri M., Miccheli A., Manetti C., and Conti F. Acetyl-l-carnitine modulates glucose metabolism and stimulates glycogen synthesis in rat brain. Brain Res. 796 (1998) 75-81
4. Bartolini G., Orlandi M., Ammar K., Magrini E., Ferreri A.M., and Rocchi P. Effect of a new derivative of retinoic acid on proliferation and differentiation in human neuroblastoma cells. Anticancer Res. 23 (2003) 1495-1499
5. Capecchi P.L., Laghi Pasini F., Quartarolo E., and Di Perri T. Carnitines increase plasma levels of adenosine and ATP in humans. Vasc. Med. 2 (1997) 77-81
6. Chauhan N.B., and Siegel G.J. Effect of PPF and ALCAR on the induction of NGF- and p75-mRNA and on APP processing in Tg2576 brain. Neurochem. Int. 43 (2003) 225-233
7. Colciaghi F., Borroni B., Pastorino L., Marcello E., Zimmermann M., Cattabeni F., Padovani A., and Di Luca M. [alpha]-Secretase ADAM10 as well as [alpha]APPs is reduced in platelets and CSF of Alzheimer disease patients. Mol. Med. 8 (2002) 67-74
8. Desdouits F., Buxbaum J.D., Desdouits-Magnen J., Nairn A.C., and Greengard P. Amyloid alpha peptide formation in cell-free preparations. Regulation by protein kinase C, calmodulin, and calcineurin. J. Biol. Chem. 271 (1996) 24670-24674
9. Dewachter I., and Van Leuven F. Secretases as targets for the treatment of Alzheimer's disease: the prospects. Lancet Neurol. 1 (2002) 409-416
10. Di Luca M., Pastorino L., Cattabeni F., Zanardi R., Scarone S., Racagni G., Smeraldi E., and Perez J. Abnormal pattern of platelet APP isoforms in Alzheimer disease and Down syndrome. Arch. Neurol. 53 (1996) 1162-1166
11. Dolezal V., and Tucek S. Utilization of citrate, acetylcarnitine, acetate, pyruvate and glucose for the synthesis of acetylcholine in rat brain slices. J. Neurochem. 36 (1981) 1323-1330
12. Doody R.S. Clinical benefits of a new piperidine-class AChE inhibitor. Eur. Neuropsychopharmacol. 9 Suppl 2 (1999) S69-77
13. Eagger S.A., and Harvey R.J. Clinical heterogeneity: responders to cholinergic therapy. Alzheimer Dis. Assoc. Disord. 9 Suppl 2 (1995) 37-42
14. Farlow M. A clinical overview of cholinesterase inhibitors in Alzheimer's disease. Int. Psychogeriatr. 14 Suppl 1 (2002) 93-126
15. Gardoni F., Bellone C., Viviani B., Marinovich M., Meli E., Pellegrini-Giampietro D.E., Cattabeni F., and Di Luca M. Lack of PSD-95 drives hippocampal neuronal cell death through activation of an alpha CaMKII transduction pathway. Eur. J. Neurosci. 16 (2002) 777-786
16. 2+/calmodulin-dependent protein kinase II and postsynaptic density 95 for binding to the NR2A subunit of the NMDA receptor. J. Neurosci. 21 (2001) 1501-1509
17. Gorini A., D'Angelo A., and Villa R.F. Action of l-acetylcarnitine on different cerebral mitochondrial populations from cerebral cortex. Neurochem. Res. 23 (1998) 1485-1491
18. Haass C. Take five-BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation. Embo J. 23 (2004) 483-488
19. Hagen T.M., Ingersoll R.T., Wehr C.M., Lykkesfeldt J., Vinarsky V., Bartholomew J.C., Song M.H., and Ames B.N. Acetyl-l-carnitine fed to old rats partially restores mitochondrial function and ambulatory activity. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 9562-9566
20. Kamenetz F., Tomita T., Hsieh H., Seabrook G., Borchelt D., Iwatsubo T., Sisodia S., and Malinow R. APP processing and synaptic function. Neuron 37 (2003) 925-937
21. Kojro E., Gimpl G., Lammich S., Marz W., and Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 5815-5820
22. Kraveka J.M., Li L., Bielawski J., Obeid L.M., and Ogretmen B. Involvement of endogenous ceramide in the inhibition of telomerase activity and induction of morphologic differentiation in response to all-trans-retinoic acid in human neuroblastoma cells. Arch. Biochem. Biophys. 419 (2003) 110-119
23. Lahiri D.K., Farlow M.R., and Sambamurti K. The secretion of amyloid beta-peptides is inhibited in the tacrine-treated human neuroblastoma cells. Brain Res. Mol. Brain Res. 62 (1998) 131-140
24. Lahiri D.K., Farlow M.R., Sambamurti K., Greig N.H., Giacobini E., and Schneider L.S. A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr. Drug Targets 4 (2003) 97-112
25. Lammich S., Kojro E., Postina R., Gilbert S., Pfeiffer R., Jasionowski M., Haass C., and Fahrenholz F. Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 3922-3927
26. Lustbader J.W., Cirilli M., Lin C., Xu H.W., Takuma K., Wang N., Caspersen C., Chen X., Pollak S., Chaney M., Trinchese F., Liu S., Gunn-Moore F., Lue L.F., Walker D.G., Kuppusamy P., Zewier Z.L., Arancio O., Stern D., Yan S.S., and Wu H. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 304 (2004) 448-452
27. Marcello E., Gardoni F., Mauceri D., Romorini S., Jeromin A., Epis R., Borroni B., Cattabeni F., Sala C., Padovani A., and Di Luca M. Synapse-associated protein-97 mediates alpha-secretase ADAM10 trafficking and promotes its activity. J. Neurosci. 27 (2007) 1682-1691
28. Marks N., and Berg M.J. Neurosecretases provide strategies to treat sporadic and familial Alzheimer disorders. Neurochem. Int. 52 (2008) 184-215
29. Paradies G., Petrosillo G., Gadaleta M.N., and Ruggiero F.M. The effect of aging and acetyl-l-carnitine on the pyruvate transport and oxidation in rat heart mitochondria. FEBS Lett. 454 (1999) 207-209
30. Pettegrew J.W., Klunk W.E., Panchalingam K., Kanfer J.N., and McClure R.J. Clinical and neurochemical effects of acetyl-l-carnitine in Alzheimer's disease. Neurobiol. Aging 16 (1995) 1-4
31. Pettegrew J.W., Levine J., and McClure R.J. Acetyl-l-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression. Mol. Psychiatry 5 (2000) 616-632
32. Poongodi G.L., Suresh N., Gopinath S.C., Chang T., Inoue S., and Inoue Y. Dynamic change of neural cell adhesion molecule polysialylation on human neuroblastoma (IMR-32) and rat pheochromocytoma (PC-12) cells during growth and differentiation. J. Biol. Chem. 277 (2002) 28200-28211
33. Postina R., Schroeder A., Dewachter I., Bohl J., Schmitt U., Kojro E., Prinzen C., Endres K., Hiemke C., Blessing M., Flamez P., Dequenne A., Godaux E., van Leuven F., and Fahrenholz F. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J. Clin. Invest. 113 (2004) 1456-1464
34. Rogers S.L., and Friedhoff L.T. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. Dementia 7 (1996) 293-303
35. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81 (2001) 741-766
36. Smith M.A., Sayre L.M., Monnier V.M., and Perry G. Oxidative posttranslational modifications in Alzheimer disease. A possible pathogenic role in the formation of senile plaques and neurofibrillary tangles. Mol. Chem. Neuropathol. 28 (1996) 41-48
37. Spagnoli A., Lucca U., Menasce G., Bandera L., Cizza G., Forloni G., Tettamanti M., Frattura L., Tiraboschi P., Comelli M., et al. Long-term acetyl-l-carnitine treatment in Alzheimer's disease. Neurology 41 (1991) 1726-1732
38. Thal L.J., Carta A., Clarke W.R., Ferris S.H., Friedland R.P., Petersen R.C., Pettegrew J.W., Pfeiffer E., Raskind M.A., Sano M., Tuszynski M.H., and Woolson R.F. A 1-year multicenter placebo-controlled study of acetyl-l-carnitine in patients with Alzheimer's disease. Neurology 47 (1996) 705-711
39. Zimmermann M., Borroni B., Cattabeni F., Padovani A., and Di Luca M. Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients. Neurobiol. Dis. 19 (2005) 237-242
40. Zimmermann M., Gardoni F., Marcello E., Colciaghi F., Borroni B., Padovani A., Cattabeni F., and Di Luca M. Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines. J. Neurochem. 90 (2004) 1489-1499